Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Atea Pharmaceuticals Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q4, Atea Pharmaceuticals (NASDAQ:AVIR) earned $117.13 million, a 515.45% increase from the preceding quarter. Atea Pharmaceuticals also posted a total of $192.18 million in sales, a 485.72% increase since Q3. Atea Pharmaceuticals collected $32.81 million in revenue during Q3, but reported earnings showed a $28.19 million loss.

Why Is ROIC Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.